ReviewJournal of cardiovascular echography
Role of Tei Index in Early Detection of Anthracycline-induced Cardiotoxicity.
Review in Journal of cardiovascular echography. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although anthracycline chemotherapy is widely used in different types of cancer, they are commonly known to induce cardiotoxicity. Early diagnosis of cardiotoxicity induced by cancer therapy is of great interest. Due to the insensitivity of left ventricular ejection fraction (LVEF) in the early identification of cardiotoxicity, global longitudinal strain (GLS) has become the best approach for early cardiotoxicity identification. The goal of our research was to assess the function of the Tei Index, a relatively new tool for evaluating both diastolic and systolic function, in the prediction of cardiac dysfunction. Materials and Methods: One hundred patients were enrolled in our prospective observational study. Demographic and clinical data were collected at the first visit. Assessments of LVEF, GLS, and the Tei Index were taken before initiation of therapy and subsequently at 3- and 6-month intervals (2 Results: The patients' mean age was 44.79 ± 14.26 years, predominantly females (76%). The mean LVEF fell from 63.44 ± 3.61 to 59.90 ± 6.00 6 months following chemotherapy. At the 6-month visit, 16% patients developed evident impairment in left ventricular systolic function with LVEF below 55%. The mean GLS at the first visit was 19.94 ± 2.68 and showed a significant decrease in its values to 17.27 ± 2.1 6 months postchemotherapy, with 20% of patients having a percentage change in GLS ≥15% (subclinical cardiotoxicity). Mean Tei Index has been significantly increased from 0.42 ± 0.09 at the first visit to 0.52 ± 0.08 at the third visit. After 6 months postchemotherapy, there was a significant inverse relationship between ejection fraction (EF) and Tei Index ( Conclusion: Tei Index is a good negative test for ruling out the cardiac dysfunction, but not for confirming the condition. Keep in mind, follow up should be lasted longer for further assessment of the cardiac dysfunction that may become evident at longer periods. However, our primary purpose was to look for early signs of cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.